Table 2.
Results base case model per surveillance strategy for low and high risk of LRR
| Hospital-based strategy | NBCSP-based strategy | |||||||
|---|---|---|---|---|---|---|---|---|
| Low risk of LRR | High risk of LRR | Low risk of LRR | High risk of LRR | |||||
| Total number of TTR (positive TTR, negative TTR) | 26,663 | 24,883 | 13,534 | 12,923 | ||||
| 13 (0.2%) | 26,650 (99.8%) | 440 (6.5%) | 24,443 (93.5%) | 8 (0.1%) | 13,526 (99.9%) | 387 (5.7%) | 12,536 (94,3%) | |
| Total costs (€) surveillance | 2,529,150 | 2,367,616 | 1,063,530 | 1,013,224 | ||||
| Total costs (€) of treatment | 169,152 | 5,082,534 | 208,136 | 5,926,590 | ||||
| Final costs (€) | 2,698,302 | 7,450,150 | 1,271,666 | 6,939,814 | ||||
| Early vs late detection of LRR (%) | 10 early, 3 late (0.14, 0.04) | 298 early, 142 late (4.39, 2.09) | 2 early, 6 late (0.03, 0.09) | 113 early, 274 late (1.66, 4.03) | ||||
| Self-detected LRRs after 5 years (%) | 3 (0.04) | 17 (0.25) | 8 (0.11) | 66 (0.97) | ||||
| False positive test results resulting in extra diagnostic tests (%) | 461 (6.55) | 423 (6.23) | 234 (3.32) | 217 (3.19) | ||||
TTR = True (positive and/or negative) Test Results
LRR = Locoregional Recurrence